Clinical development strategy and study design guidance
Armstrong Clinical provides clinical development strategy and study design guidance to biopharmaceutical companies and medical research institutes.
We add value across the clinical development lifecycle from Phase I studies through to Phase IV with sound regulatory insights, design options, gated target planning, study complexity, implementation and location advice.
Specialists at Armstrong Clinical work with you to tailor your clinical studies and development programs, decrease risk and meet regulatory, developmental, commercial, budget and time objectives.
At the moment following services are available:
Clinical Development: Path to Market
Rapidly evolving study designs and development strategies mean more effective early studies, shorter development programs and precision outcomes. Understand how complex adaptive designs, predictive modelling, etc. can create precision and reduce your development time and cost.
READ MORE
Phase I and IIa Study Designs
We work with you to design or review your planned early phase clinical studies. Our experience designing simple to modern, complex early phase studies will help taylor a design to suit your therapy, indication and company objectives.
READ MORE
Study Location and CRO Selection
Looking to conduct your early phase in Australia? It’s important the CRO and Clinical Site best suited to your organisation, disease are and project. is selected. We can help advise where best to conduct your early phase study and with who.
READ MORE
Clinical Development of Today
Tools and techniques of study design and development strategy are evolving rapidly to generate more efficient studies, programs and precision outcomes. Understand when and how complex adaptive designs, predictive modelling, etc. can be utilised to create precision and reduce your development time and cost.
READ MORE